The SARS-CoV-2 pandemic introduced the world to a new type of vaccine based on mRNA
encapsulated in lipid nanoparticles (LNPs). Instead of delivering antigenic proteins directly …

Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …

Passive immunization with broadly neutralizing antibodies (bnAbs) is a promising approach
to reduce the 1.7 million annual human immunodeficiency virus (HIV) infections globally …

Current approaches to reducing the latent HIV reservoir entail first reactivating virus-
containing cells to become visible to the immune system. A critical second step is killing …

HIV-1 broadly neutralizing antibodies (bNAbs) can decrease viremia but are usually unable
to counteract autologous viruses escaping the antibody pressure. Nonetheless, bNAbs may …

In the last decade, over a dozen potent broadly neutralizing antibodies (bnAbs) to several
HIV envelope protein epitopes have been identified, and their in vitro neutralization profiles …

Introduction: Given the complexities of HIV infection and the HIV genetic heterogeneity, a
successful HIV vaccine should elicit broad adaptive and innate immune responses. Vaccine …

Decrypting the B cell ontogeny of HIV-1 broadly neutralizing antibodies (bNAbs) is
paramount for vaccine design. Here, we characterized IgA and IgG bNAbs of three distinct B …

The fusion peptide (FP) of HIV-1 envelope glycoprotein (Env) is essential for mediating viral
entry. Detection of broadly neutralizing antibodies (bnAbs) that interact with the FP has …

Introduction The last 12 years have seen remarkable progress in the isolation and
characterization of at least five different epitope classes of HIV‐specific broadly neutralizing …